Interventional Cardiology
|
|
- Marjorie Cunningham
- 5 years ago
- Views:
Transcription
1 Interventional Cardiology Cost effectiveness of fractional flow reserve-guided percutaneous coronary intervention In recent years, fractional flow reserve (FFR) has become accepted as a clinically effective tool for guiding decisions about percutaneous coronary intervention (PCI). FFR poses a unique alternative to stress testing or angiography-guided PCI, in that it can interrogate the ischemic potential of an individual vessel on an impromptu basis once an angiogram is in progress, offering immediate data for decision making. With its recent greater adoption across the USA, its effectiveness has become an important consideration. There have been a few key analyses over the last decade demonstrating the effectiveness of FFR-guided PCI; we review the major effectiveness analyses, showing the economic utility of FFR-guided PCI for the modern interventionalist. Freddy Abnousi1, Celina Yong1 & William Fearon*,1 1 Division of Cardiovascular Medicine, Stanford University Medical Center, 3 Pasteur Drive, Room H213, Stanford, CA 9435, USA *Author for correspondence: Tel.: Fax: wfearon@ stanford.edu Keywords: effectiveness fractional flow reserve percutaneous coronary intervention Although angiography is the established invasive approach for assessing coronary artery disease, its ability to evaluate the functional significance of stenoses is limited. Currently, the available options for assessing the hemodynamic significance of lesions include noninvasive functional testing, such as stress echocardiography or stress perfusion scintigraphy (SPS), or invasive testing, with fractional flow reserve (FFR). FFR is defined as the ratio of the distal coronary pressure to the proximal pressure during maximum hyperemia. It has been shown to be an effective method for guiding revascularization [1 6]. As such, it has received a class IA recommendation from the European Society of Cardiology and a class IIA recommendation from the American College of Cardiology [7,8]. Its clinical effectiveness was demonstrated in the FAME trial [2], which compared angiography guided PCI with FFR-guided PCI in patients with multivessel coronary disease. This prospective, multicenter, international trial randomly assigned 15 patients with multivessel coronary disease to either PCI guided by FFR (PCI if FFR.8) or by angiography alone. Of note, this trial included /ica Future Medicine Ltd patients presenting with acute coronary syndrome, with certain limitations (any ST elevation myocardial infarction had to occur more than 5 days prior to PCI, and in the case of non-st elevation myocardial infarction, peak creatine kinase level had to be less than 1 U/l). The trial met its primary endpoint of death, myocardial infarction, and repeat revascularization at 1 year, with an event rate of 18.3% in the angiography guided PCI group and 13.2% in the FFRguided PCI group (p =.2). Subsequently, the FAME 2 clinical trial [9] was designed to test whether optimal medical therapy alone was superior to FFR-guided PCI plus optimal medical therapy in patients with stable coronary disease. Recruitment was halted early in this prospective, multi-center, international trial of 122 patients (of whom 888 underwent randomization) due to an early finding of a significant difference between the groups in the primary endpoint event (death from any cause, myocardial infarction, or unplanned hospitalization leading to urgent revascularization). The PCI group had a primary event at a rate of 4.3% as compared with the medical therapy group Interv. Cardiol. (215) 7(4), part of ISSN
2 Abnousi, Yong & Fearon that had an event rate of 12.7% (HR with PCI:.32; 95% CI:.19.53; p <.1). Of note, a lower rate of urgent revascularization in the PCI group drove this difference (1.6 vs 11.1%; HR:.13; 95% CI:.6.3; p <.1). Recently, the 2-year results of FAME 2 showed similar primary endpoint trajectories (8.1% event rate for the PCI group vs 19.5% event rate for the medical therapy group; HR:.39; 95% CI:.26.57; p <.1), driven by urgent revascularization (4.% in the PCI group vs 16.3% in the medical therapy group; HR:.23; 95% CI:.14.38; p <.1). Additionally, though there were no significant differences between groups in myocardial infarction or death overall; notably, if the first week of outcomes was excluded to eliminate periprocedural events, there were significantly lower rates of myocardial infarction and death at two years for the PCI group (4.6 vs 8.%; p =.4) [1]. FFR has not only shown clinical utility, but also economic utility, with robust evidence demonstrating its effectiveness. Fearon et al. [11] first used computer modeling to compare three potential strategies for deciding whether or not to perform PCI on an intermediate lesion: 1) NUC strategy deferring the decision for PCI to obtain nuclear stress imaging; 2) FFR strategy using FFR to guide PCI at the time of; 3) STENT strategy stenting all moderate lesions without further evidence of hemodynamic signifi12 P <.1 SPS-group FFR-group P < Total Cath lab Equipment Contrast RN/RT P <.5 Post-Cath Cost ($) 1 Figure 1. Costs incurred in the cath lab in patients who were randomized to stress perfusion scintigraphy versus fractional flow reserve. The itemized s include: RN/ RT, post-cath (the time that RN and RT spent per patient during and after cardiac catheterization multiplied by the hourly wages), contrast and equipment (the s of the WaveWire, guiding catheter and Tuohy steering kit). Values are means +/- SEM. Adapted with permission from Leesar et al. [12]. FFR: Fractional flow reserve; RN: Registered nurse; RT: Radiologic technologist; SPS: Stress perfusion scintigraphy. 388 Interv. Cardiol. (215) 7(4) cance. They used marginal s for both in-hospital and outpatient services to optimally estimate the of performing additional procedures. They measured the FFR as $761 (consisting of $55 for the wire, $36 for intracoronary adenosine and $175 for professional fees). Nuclear stress imaging was estimated to $193. Based on prior published data, the medical of treating angina was $1775 per year. They assumed an estimated repeat PCI rate after stenting of 11% at 1 year and 2.5% per year for the next 4 years. Based on these calculations, the FFR strategy provided a savings of $1795 per patient as compared with the NUC strategy, and $383 per patient as compared with the STENT strategy. Additionally, in terms of per quality-adjusted life-years (QALY) gained, though the NUC strategy was expensive (>$8,/QALY), both FFR and NUC strategies were superior to the STENT strategy. Conclusions from this study are limited by the general limitations of modeling work, which require a number of assumptions to arrive at the conclusions. Leesar et al. [12] provided the first clinical data by evaluating the impact of FFR compared with SPS in patients with unstable angina (UA) or non-st elevation myocardial infarction (NSTEMI) (Figure 1). Specifically, 7 patients with UA/NSTEMI (312 patients originally screened) and single vessel disease with moderate stenoses based on coronary angiography were randomized to SPS (35 patients) or FFR (35 patients). In both groups, the patients were discharged and managed medically if ischemia was not present, otherwise PCI was performed on the lesion. They found that the FFR approach significantly decreased the ($1,329 ± $44 vs $2,113 ± $12; p <.5) and duration of hospitalization (11 ± 2 h vs 49 ± 5 h; p <.1). Arguably, a limitation of this comparison study is that it does not capture the potential value of using stress testing to guide PCI if performed prior to angiogram. The approach of taking a patient off the cardiac catheterization table after the angiogram to subsequently pursue stress imaging before returning to fix a lesion is the most expensive way to use stress imaging to guide coronary interventions. However, this study reinforced the safety and effectiveness of using FFR to defer PCI of hemodynamically insignificant lesions, even in the presence of an acute coronary syndrome. In looking at the effectiveness of FFR from a large randomized clinical trial perspective, the FAME investigators conducted an analysis prospectively in the FAME trial described above [13]. This study found that QALYs showed a nonsignificant trend to be higher in the FFR-guided arm compared with the angio-guided group (.853 vs.838; p =.2) and the
3 Cost effectiveness of FFR-guided PCI mean overall s at 1 year were significantly less in the FFR-guided arm ($14,315 vs 16,7; p <.1). Although the use of the pressure wire and adenosine adds, the reduction in unnecessary drug-eluting stenting and the decrease in adverse events lead to lower resource utilization in the FFR-guided PCI group compared with the angio-guided PCI group. Additionally, bootstrap simulation showed that the FFR-guided strategy was unique for a new technology. Many new techniques improve outcomes, but usually more money. FFR-guided PCI was found to be -saving (improve outcomes and less) in 91% and effective at a threshold of US $5, per QALY in 99.96% (Figure 2). Additionally, sensitivity analyses showed robust results. Specifically, analyses were performed with ± 2% on prices and ± 1% on utilities, with the end results always favoring the FFR group. Note that one of this study s limitations was that it applied US s to the analysis, while the majority of patients were from outside the USA. The FAME investigators also demonstrated the economic attractiveness of FFR-guided PCI in comparison to optimal medical therapy in the analysis of the FAME 2 clinical trial data [14]. Of note, the direct effectiveness of FFR itself is difficult to assume from this analysis, as all patients underwent FFR for this trial. As expected, initial s were significantly higher for the FFR-guided PCI group ($9927 vs 39; p <.1) because of the of the drug-e luting Incremental [$] 5 4 ICER of 5, $ / QALY FFR guidance improves outcomes Incremental QALY -2-3 FFR guidance saves resources -4-5 Figure 2. Bootstrap simulation of incremental s and effects. Numbers on axes represent differences between FFRguided and angiography-guided strategies. Positive incremental QALYs indicate higher effectiveness for FFR-guided treatment. Negative incremental s indicate lower s for FFR-guided treatment compared with angiographyguided strategy. Data are from 5 bootstrap replications. Adapted with permission from Fearon et al. [13]. FFR: Fractional flow reserve; QALY: Quality-adjusted life-years
4 Abnousi, Yong & Fearon Cumulative ($) 14, 12, $2,883 1, 8, $6,27 6, 4, 2, FFR-guided PCI Medical therapy Follow-up (months) Figure 3. Cumulative medical s (vertical axis) of a strategy of PCI in the setting of an abnormal FFR (solid line) and a medical therapy strategy (dashed line) over 12 months of follow-up (horizontal axis). Adapted with permission from Fearon et al. [14]. FFR: Fractional flow reserve; PCI: Percutaneous coronary intervention. stenting. However, during the first year, this margin narrowed from $627 to $2883 (p <.1) driven primarily by the of subsequent revascularization in the medical therapy arm (Figure 3). In terms of patient utility, the FFR group had significant benefits at 1 month (.54 vs.1 units; p <.1). Overall, this led to a effectiveness ratio of FFR-guided PCI compared with optimal medical therapy to be $36,/QALY (Figure 4). This study was mainly limited by the early halt in recruitment secondary to the recommendation by the Data Safety Monitoring Board. This led to the need for a number of assumptions with regards to s and PCI durability (the benefit of PCI would diminish to zero over 3 years) in order to be able to forecast results. The effectiveness of FFR has also been evaluated outside the USA. Sengottuvelu et al. performed an analysis of a small Indian population, comparing FFR-guided decision making to what an independent reviewing cardiologist would have decided based on angiography alone [15]. They found a net benefit in favor of FFR-based management of $15,6. A prospective economic evaluation comparing FFR versus angiography in patients with multivessel disease evaluated the effectiveness and budget impact for Australia [16]. Using Australian utilities and s, they showed that FFR was -saving and reduces s by 1776 AD per patient per year. Over 2 years, the public health impact ranged from 7.8 to 73.9 QALYs gained with a budget impact from 1.8 to 14.5 million AUD total savings. Further studies are necessary to evaluate whether these findings are generalizable to 39 Interv. Cardiol. (215) 7(4) different national medical systems that reimburse and finance medical care in different ways. In comparing FFR to other non-invasive modalities, computed tomography based FFR (FFRCT ) has been studied through modeling. FFRCT applies computational fluid dynamics to images from computed tomography angiography (ccta) to noninvasively quantify FFR of coronary arteries [17]. Hlatky et al. [17] simulated a number of scenarios that evaluated the novel strategy of FFRCT from Heartflow Inc. Specifically, clinical data from 96 patients in the DISCOVER-FLOW [18] trial and literature-based outcomes data were combined to forecast initial management s and 1 year death/mi rates associated with five strategies: 1) invasive angiography-guided PCI; 2) invasive coronary angiography and invasive FFR-guided PCI; 3) ccta-guided PCI; 4) ccta followed by invasive FFR-guided PCI; and, 5) ccta and FFRCT-guided PCI. The approaches that did not evaluate hemodynamic significance of lesions had the most expensive initial (invasive angiography guided PCI at $1,72, and ccta guided PCI at $9635). Additionally, these approaches had the greatest rate of death and MI at 1 year (invasive angiography guided PCI 2.63%, and ccta guided PCI at 2.56%). On the other hand, invasive angiography and invasive FFR-guided PCI had an initial of $8499 with a projected 1-year death and MI rate at 1.96%, as compared with the ccta and FFRCT-guided PCI strategy that had an initial of $7674 with an accompanied one year death and MI rate of 2.31%. Finally, the ccta followed by invasive FFR-guided PCI strategy had a of $835 and 1-year death and MI rate of 2.6%. Although FFRCT holds promise and may eventually become widely applicable, larger trials are needed to assess its validity. Additionally, since coronary analysis by CT is limited in the setting of calcification (which is common in our elderly patient population), this may limit how widely we can use the FFRCT modality. Finally, as is inherently a limitation to all modeling studies, this study relies on numerous assumptions for their effectiveness outcomes. Conclusion FFR is a -effective tool to determine the hemodynamic significance of coronary lesions, and can be used to guide appropriate PCI in the -conscious setting. However, its adoption is still relatively low in the USA and remains to be fully evaluated in different medical systems and among diverse patient groups. Future perspective Current use of FFR is still limited; a nationwide survey of 189 interventionalists reported that they use FFR measurement in less than one third of cases and 15%
5 Cost effectiveness of FFR-guided PCI Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript. 8 6 Difference in s ($) never use it [19]. However, in the coming decade, further developments in the pharmacology and technology of FFR-guided PCI may push adoption of its use even further. For example, it will be interesting to see the role that FFRCT-guided PCI will play once more widely adapted. While FFRCT may become a powerful noninvasive tool for predicting hemodynamically significant coronary lesions, we anticipate a continued role for traditional FFR for a large p roportion of patients who may not receive ccta imaging before angiogram or have calcified vessels that preclude accurate CT imaging. With continued innovation, a host of FFR modalities will offer options for the modern interventionalist s toolkit; and in the setting of skyrocketing healthcare s, it will be important to continue to focus on the effectiveness of each of these options $15, $1, $5, Difference in QALYS Figure 4. Bootstrap replications of the incremental effectiveness of the strategy of percutaneous coronary intervention in the setting of an abnormal fractional flow reserve compared with best medical therapy. Each of the 1, points represents the results of one bootstrap replication. The difference in cumulative s is displayed in the vertical axis, and the difference in QALYs is displayed on the horizontal axis. Willingnessto-pay thresholds of $5, per QALY added (solid line), $1, per QALY added (dashed line), and $15, per QALY added (dotted line) are indicated in the plane. The fractions of replications in each sector of the plane are indicated (e.g.,.23 of the replications had a difference < and QALY difference >). Adapted with permission from Fearon et al. [14 QALY: Quality-adjusted life-years. Executive summary There is strong evidence to support the use of fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) of moderate coronary lesions. Economic modeling as well as clinical data from large trials show savings. FAME I compared FFR-guided PCI to angiography and showed that FFR-guided PCI was -effective at a threshold of US $5,/quality-adjusted life-years (QALY). FAME II compared FFR-guided PCI to optimal medical therapy and showed that FFR-guided PCI had a effectiveness ratio of $36,/QALY. Newer, less invasive FFR technologies have the potential to expand interventionalists options for effective hemodynamic assessment of moderate coronary lesions in the near future. References Landmark clinical trial. Papers of special note have been highlighted as: of interest; of considerable interest 3 Pijls NHJ, De Bruyne B, Peels K et al. Measurement of fractional flow reserve to assess the functional severity of coronary artery stenoses. N. Engl. J. Med. 334, (1996). 1 2 Bech GJ, De Bruyne B, Pijls NHJ et al. Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial. Circulation 13, (21). Tonino PA, De Bruyne B, Pijls NH et al. FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N. Engl. J. Med. 36, (29). Provides a historical perspective. 4 Hamilos M, Muller O, Cuisset T et al. Long-term clinical outcome after fractional flow reserve guided treatment in patients with angiographically equivocal left main coronary artery stenosis. Circulation 12, (29)
6 Abnousi, Yong & Fearon 5 Muller O, Mangiacapra F, Ntalianis A et al. Long-term follow-up after fractional flow reserve-guided treatment strategy in patients with an isolated proximal left anterior descending coronary artery stenosis. JACC Cardiovasc. Interv. 4, (211). 6 Puymirat E, Peace A, Mangiacapra F et al. Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary revascularization in patients with small-vessel disease. Circ. Cardiovasc. Interv. 5, (212) Fearon WF, Bornschein B, Tonino PA et al. Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) Study Investigators. Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. Circulation 122(24), (21). Analysis from a landmark clinical trial. 14 Fearon WF, Shilane D, Pijls NH et al. Fractional Flow Reserve Versus Angiography for Multivessel Evaluation 2 (FAME 2) Investigators. Cost-effectiveness of percutaneous coronary intervention in patients with stable coronary artery disease and abnormal fractional flow reserve. Circulation 128(12), (213). Analysis from landmark clinical trial. 15 Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization: the Task Force on Myocardial Revascu- larization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 31, (21). Sengottuvelu G, Chakravarthy B, Rajendran R, Ravi S. Clinical usefulness and effectiveness of fractional flow reserve among Indian patients (FIND study). Catheter. Cardiovasc. Interv. doi: 1.12/ccd (214)(Epub ahead of print). 16 De Bruyne B, Pijls NH, Kalesan B et al. FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N. Engl. J. Med. 367, (212). Siebert U, Arvandi M, Gothe RM et al. Improving the quality of percutaneous revascularisation in patients with multivessel disease in Australia: -effectiveness, public health implications, and budget impact of FFR-guided PCI. Heart Lung Circ. 23(6), (214). 17 Hlatky MA, Saxena A, Koo BK, Erglis A, Zarins CK, Min JK. Projected s and consequences of computed tomography-determined fractional flow reserve. Clin. Cardiol. 36(12), (213). Kushner FG, Hand M, Smith SC Jr et al. 29 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 24 guideline and 27 focused update) and ACC/ AHA/SCAI guidelines on percutaneous coronary intervention (updating the 25 guideline and 27 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 12, (29). Landmark clinical trial. 1 De Bruyne B, Fearon WF, Pijls NH et al. FAME 2 Trial Investigators. Fractional flow reserve-guided PCI for stable coronary artery disease. N. Engl. J. Med. 371(13), (214). 11 Fearon WF, Yeung AC, Lee DP, Yock PG, Heidenreich PA. Cost-effectiveness of measuring fractional flow reserve to guide coronary interventions. Am. Heart J. 145(5), (23). 12 Leesar MA, Abdul-Baki T, Akkus NI, Sharma A, Kannan T, Bolli R. Use of fractional flow reserve versus stress perfusion scintigraphy after unstable angina. Effect on duration of hospitalization,, procedural characteristics, and clinical outcome. J. Am. Coll. Cardiol. 41(7), (23). Interv. Cardiol. (215) 7(4) Analysis looking at promising novel technology. 18 Koo BK, Erglis A, Doh JH et al. Diagnosis of ischemiacausing coronary stenoses by noninvasive fractional flow reserve computed from coronary computed tomographic angiograms: results from the prospective multicenter DISCOVER-FLOW (Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive Fractional Flow Reserve) study. J. Am. Coll. Cardiol. 58, (211). 19 Bashar Hannawi, Wilson W, Lam Suwei Wang, George A Younis. Current use of fractional flow reserve: a nationwide survey. Tex. Heart Inst. J. 41(6), (214).
Cost-Effectiveness of Fractional Flow Reserve
Cost-Effectiveness of Fractional Flow Reserve William F. Fearon, MD Associate Professor of Medicine Director, Interventional Cardiology Stanford University Medical Center Cost-Effectiveness of FFR What
More informationFractional Flow Reserve (FFR) Shown to Improve Patient Outcomes and Reduce Costs. Executive Summary
(FFR) Shown to Improve Patient Outcomes and Reduce s Keywords Fractional Flow Reserve, coronary artery disease, stenosis, blood flow blockages Published: 5 October 213 Citation: RadcliffeCardiology.com,
More informationFractional Flow Reserve: Basics, FAME 1, FAME 2. William F. Fearon, MD Associate Professor Stanford University Medical Center
Fractional Flow Reserve: Basics, FAME 1, FAME 2 William F. Fearon, MD Associate Professor Stanford University Medical Center Conflict of Interest Advisory Board for HeartFlow Research grant from St. Jude
More informationFractional Flow Reserve: Review of the latest data
Fractional Flow Reserve: Review of the latest data Michalis Hamilos, MD, PhD, FESC University Hospital of Heraklion Fractional Flow Reserve (FFR) Coronary angiography does not always tell the truth Most
More informationFFR-Guided PCI. 4 th Imaging and Physiology Summit October 29 th, 2010 Seoul, Korea. Stanford
4 th Imaging and Physiology Summit October 29 th, 2010 Seoul, Korea FFR-Guided PCI William F. Fearon, M.D. Associate Professor Division of Cardiovascular Medicine University Medical Center Disclosure Statement
More informationBenefit of Performing PCI Based on FFR
Benefit of Performing PCI Based on FFR William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Benefit of FFR-Guided PCI FFR-Guided PCI vs. Angiography-Guided
More informationCost analysis of non-invasive fractional flow reserve derived from coronary computed tomographic angiography in Japan
Cardiovasc Interv and Ther (2015) 30:38 44 DOI 10.1007/s12928-014-0285-1 ORIGINAL ARTICLE Cost analysis of non-invasive fractional flow reserve derived from coronary computed tomographic angiography in
More informationPCIs on Intermediate Lesions NCDR Cath-PCI Registry
Practical Application Of Coronary Physiology in The Cath Lab Talal T Attar, MD, MBA, FACC PCIs on Intermediate Lesions NCDR Cath-PCI Registry Fraction of stenoses 50-70% treated with PCI without further
More informationFFR Incorporating & Expanding it s use in Clinical Practice
FFR Incorporating & Expanding it s use in Clinical Practice Suleiman Kharabsheh, MD Consultant Invasive Cardiology Assistant professor, Alfaisal Univ. KFHI - KFSHRC Concept of FFR Maximum flow down a vessel
More information3 Year Clinical Outcome and Cost-Effectiveness of FFR- Guided PCI in Stable Patients with Coronary Artery Disease: FAME 2 Trial
3 Year Clinical Outcome and Cost-Effectiveness of FFR- Guided PCI in Stable Patients with Coronary Artery Disease: FAME 2 Trial William F. Fearon, MD, Takeshi Nishi, MD, Bernard De Bruyne, MD, PhD, Derek
More informationCoronary stenting: the appropriate use of FFR
Coronary stenting: the appropriate use of FFR Morton J. Kern, MD Professor of Medicine Chief of Cardiology LBVA Associate Chief Cardiology University California Irvine Orange, California To treat or not
More informationFractional Flow Reserve and the Results of the FAME Study
Imaging and Physiology Summit Seoul, Korea November 21 st, 2009 Fractional Flow Reserve and the Results of the FAME Study William F. Fearon, M.D. Assistant Professor Division of Cardiovascular Medicine
More informationFFR in Multivessel Disease
FFR in Multivessel Disease April, 26 2013 Coronary Physiology in the Catheterization Laboratory Location: European Heart House, Nice, France Pim A.L. Tonino, MD, PhD Hartcentrum, Eindhoven, the Netherlands
More informationFRACTIONAL FLOW RESERVE: STANDARD OF CARE
FRACTIONAL FLOW RESERVE: FROM INVESTIGATIONAL TOOL TO STANDARD OF CARE TCT ASIA Seoul, Korea, april 26 th, 2012 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands FRACTIONAL FLOW
More informationΣεμινάριο Ομάδων Εργασίας Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική
ΕΛΛΗΝΙΚΗΚΑΡΔΙΟΛΟΓΙΚΗΕΤΑΙΡΕΙΑ Σεμινάριο Ομάδων Εργασίας 2011 Fractional Flow Reserve (FFR) Σε ποιούς ασθενείς; ΔΗΜΗΤΡΗΣ ΑΥΖΩΤΗΣ Επιστ. υπεύθυνος Αιμοδυναμικού Τμήματος, Βιοκλινική GUIDELINES ON MYOCARDIAL
More informationCLINICAL CONSEQUENCES OF THE
CLINICAL CONSEQUENCES OF THE FAME STUDY TCT ASIA Seoul, Korea, april 26 th, 2012 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands GUIDELINES ESC SEPTEMBER 2010 FFR UPGRADED TO LEVEL
More informationCost-effectiveness of measuring fractional flow reserve to guide coronary interventions Fearon W F, Yeung A C, Lee D P, Yock P G, Heidenreich P A
Cost-effectiveness of measuring fractional flow reserve to guide coronary interventions Fearon W F, Yeung A C, Lee D P, Yock P G, Heidenreich P A Record Status This is a critical abstract of an economic
More informationPressureWire Agile Tip Technology
PressureWire Agile Tip Technology FINALLY. INTRODUCING PRESSUREWIRE WITH AGILE TIP St. Jude Medical continues to set new standards in fractional flow reserve (FFR) measurement. With the next generation
More informationCoronary artery disease (CAD): Fractional Flow Reserve (FFR) for Pilots Risk Assessment. B. Haaff, R. Quast
Coronary artery disease (CAD): Fractional Flow Reserve (FFR) for Pilots Risk Assessment B. Haaff, R. Quast Aeromedical Center Germany, Stuttgart-Airport Westpfalz-Klinikum, Kaiserslautern, Germany Disclosure
More informationRelations of Interest
Relations of Interest Consulting Fees on my behalf go to the Cardiovascular Research Center Aalst Contracted Research between the Cardiovascular Research Center Aalst and several pharmaceutical and device
More informationCT FFR: Are you ready to totally change the way you diagnose Coronary Artery Disease?
CT FFR: Are you ready to totally change the way you diagnose Coronary Artery Disease? Madan Mohan MD MRCP FACC CQO, Division of Cardiovascular Medicine University Hospitals Case Medical Center Assistant
More informationFAME STUDY: 2-year Follow-Up & CLINICAL SUBGROUP ANALYSIS
Coronary Physiology In The Cathlab FAME STUDY: 2-year Follow-Up & CLINICAL SUBGROUP ANALYSIS Educational Training Program ESC European Heart House april 7th 9th 2011 Nico H.J.Pijls, MD, PhD Catharina Hospital,
More informationManagement of stable CAD FFR guided therapy: the new gold standard
Management of stable CAD FFR guided therapy: the new gold standard Suleiman Kharabsheh, MD Director; CCU, Telemetry and CHU Associate professor of Cardiology, Alfaisal Univ. KFHI - KFSHRC Should patients
More informationDo stents deserve the bad press? Mark A. Tulli MD, FACC
Do stents deserve the bad press? Mark A. Tulli MD, FACC Disclosures: None Introduction Stents don t help people. Stents are bad for patients. Heart Treatment Overused WSJ Study Finds Doctors Often Too
More informationFractional flow reserve application in everyday practice: adherence to clinical recommendations
Original Article Fractional flow reserve application in everyday practice: adherence to clinical recommendations Katia Orvin 1,2, Tamir Bental 1,2, Alon Eisen 1,2, Hana Vaknin-Assa 1,2, Abid Assali 1,2,
More informationDave Kettles, St Dominics Hospital East London.
Dave Kettles, St Dominics Hospital East London. 110 x 150 Angina for a couple of months Trop T negative T wave inversion across the chest leads Not wanting to risk radial Huge struggle with femoral
More informationFFR= Qs/Qn. Ohm s law R= P/Q Q=P/R
32 ο Πανελλήνιο Καρδιολογικό Συνζδριο, Θεσσαλονίκη 20/10/2011 Gould KL et al, JACC CARDIOVASC IMAG 2009 Gould KL et al AM J CARDIOL 1974 & JACC CARDIOVASC IMAG 2009 Under maximal hyperemia: Rs=Rn FFR=
More informationCoronary Physiology the current state of play
Coronary Physiology the current state of play Background The concept of using the trans-stenotic pressure gradient in a diseased coronary artery as a measure to guide percutaneous coronary intervention
More informationFractional Flow Reserve: The Past, Present and Future
Review Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Fractional Flow Reserve: The Past, Present and Future Jeong-Eun Kim, MD and Bon-Kwon Koo, MD Department of Internal Medicine
More informationShould we be using fractional flow reserve more routinely to select stable coronary patients for percutaneous coronary intervention?
REVIEW C URRENT OPINION Should we be using fractional flow reserve more routinely to select stable coronary patients for percutaneous coronary intervention? Seung-Jung Park and Jung-Min Ahn Purpose of
More informationIntroducing. Integrated FFR Platform
Introducing Integrated FFR Platform Fractional Flow Reserve (FFR) Definition of FFR Maximum achievable blood flow in stenotic coronary artery divided by maximum blood flow in the same artery without stenosis.
More informationPhysiology (FFR & IFR) is Essential in Daily Pratice. Martine Gilard Brest University - France
Physiology (FFR & IFR) is Essential in Daily Pratice Martine Gilard Brest University - France Background Invasive assessment of atherosclerotic coronary artery lesion Morphological assessment IVUS X-ray
More informationFractional Flow Reserve (FFR)
Non-invasive FFR using coronary CT angiography and computational fluid dyn amics predicts the hemodynamic signifi cance of coronary lesions First in man experience with CT-Flow Andrejs Erglis, Sanda Jegere,
More informationAnatomy is Destiny, But Physiology is Here Today
Published on Journal of Invasive Cardiology (http://www.invasivecardiology.com) September, 2010 [1] Anatomy is Destiny, But Physiology is Here Today Thu, 9/9/10-10:54am 0 Comments Section: Commentary Issue
More informationFFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium
FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium Conflict of Interest Institutional research grants and speaker s fee from St. Jude Medical and Boston Scientic to Cardiovascular
More informationFractional Flow Reserve from Coronary CT Angiography (and some neat CT images)
Fractional Flow Reserve from Coronary CT Angiography (and some neat CT images) Victor Cheng, M.D. Director, Cardiovascular CT Oklahoma Heart Institute 1 Disclosures Tornadoes scare me 2 Treating CAD Fixing
More informationEvidence for myocardial CT perfusion imaging in the diagnosis of hemodynamically significant coronary artery disease
Editorial Evidence for myocardial CT perfusion imaging in the diagnosis of hemodynamically significant coronary artery disease Zhonghua Sun Discipline of Medical Imaging, Department of Imaging and Applied
More informationFRACTIONAL FLOW RESERVE Step-by-step measurement, Practical tips & Pitfalls
FRACTIONAL FLOW RESERVE Step-by-step measurement, Practical tips & Pitfalls Ahmed M ElGuindy, MSc, MRCP(UK) Division of Cardiology Aswan Heart Centre 2013 Fractional Flow Reserve Essential diagnostic tool
More informationThree-vessel fractional flow reserve measurement for predicting clinical prognosis in patients with coronary artery disease
Editorial Three-vessel fractional flow reserve measurement for predicting clinical prognosis in patients with coronary artery disease Takashi Kubo, Hiroki Emori, Yosuke Katayama, Kosei Terada Department
More informationEvaluation of Intermediate Coronary lesions: Can You Handle the Pressure? Jeffrey A Southard, MD May 4, 2013
Evaluation of Intermediate Coronary lesions: Can You Handle the Pressure? Jeffrey A Southard, MD May 4, 2013 Disclosures Consultant- St Jude Medical Boston Scientific Speaker- Volcano Corporation Heart
More informationFRACTIONAL FLOW RESERVE USE IN THE CATH LAB BECAUSE ANGIOGRAPHY ALONE IS NOT ENOUGH!!!!!!!!
FRACTIONAL FLOW RESERVE USE IN THE CATH LAB BECAUSE ANGIOGRAPHY ALONE IS NOT ENOUGH!!!!!!!! Juan Antonio Pastor-Cervantes,M.D FSCAI, FACC Cardiovascular Institute Memorial Regional Hospital Hollywood Florida
More informationCase report. Resistance in the cath lab : the utility of hyperemic stenosis resistance in the functional assessment of coronary artery disease
Resistance in the cath lab : the utility of hyperemic stenosis resistance in the functional assessment of coronary artery disease Kalpa De Silva, Divaka Perera Cardiovascular Division, The Rayne Institute,
More informationInterventional Cardiology
Interventional Cardiology Cost-Effectiveness of Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease and Abnormal Fractional Flow Reserve William F. Fearon, MD; David Shilane,
More informationNoninvasive Fractional Flow Reserve from Coronary CT Angiography
2016 KSC Annual Spring Scientific Conference Noninvasive Fractional Flow Reserve from Coronary CT Angiography Bon-Kwon Koo, MD, PhD, Seoul, Korea Why the hemodynamics for coronary artery disease? Twinlifemarketing.com.au
More informationAngiographic Versus Functional Severity of Coronary Artery Stenoses in the FAME Study
Journal of the American College of Cardiology Vol. 55, No. 25, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.11.096
More informationROLE OF CORONARY PRESSURE & FFR IN MULTIVESSEL DISEASE
ROLE OF CORONARY PRESSURE & FFR IN MULTIVESSEL DISEASE Angioplasty Summit TCT ASIA Seoul, Korea, april 24th, 2008 Nico H. J. Pijls, MD, PhD Catharina Hospital, Eindhoven, The Netherlands A rather common
More informationCulprit PCI vs MultiVessel PCI for Acute Myocardial Infarction
Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia
More informationFractional Flow Reserve and the 1 Year Results of the FAME Study
Imaging and Physiology Summit Seoul, Korea, November 22, 2008 Fractional Flow Reserve and the 1 Year Results of the FAME Study William F. Fearon, M.D. Assistant Professor Division of Cardiovascular Medicine
More informationFractional Flow Reserve. A physiological approach to guide complex interventions
Fractional Flow Reserve A physiological approach to guide complex interventions What is FFR? Fractional Flow Reserve (FFR) is a lesion specific, physiological index determining the hemodynamic severity
More informationCT Determination of Fractional Flow Reserve in Coronary Lesions
REVIEW CARDIOLOGY // IMAGING CT Determination of Fractional Flow Reserve in Coronary Lesions András Mester 1, Monica Chit u 2, Nora Rat 2, Diana Opincariu 1, Lehel Bordi 1, Alexandra Stănescu 1, Marius
More informationCASE from South Korea
CASE from South Korea Bon-Kwon Koo, MD, PhD, Seoul, Korea Outpatient clinic of a non-interventional cardiologist F/56 Chief complaint: Angina with recent aggravation, CCS II~III Brief history: # Stroke
More informationFractional Flow Reserve and instantaneous wave -free Ratio. Λάμπρος Κ. Μόσιαλος Επεμβατικός Καρδιολόγος ΓΝ Παπαγεωργίου
Fractional Flow Reserve and instantaneous wave -free Ratio Λάμπρος Κ. Μόσιαλος Επεμβατικός Καρδιολόγος ΓΝ Παπαγεωργίου DISCLOSURES There are no financial conflicts of interest relevant to this presentation
More informationFractional flow reserve: a new paradigm for diagnosis and management of coronary artery disease
Perspective Fractional flow reserve: a new paradigm for diagnosis and management of coronary artery disease Fractional flow reserve (FFR) is an index of the physiological significance of a coronary stenosis
More informationControversies in Cardiac Surgery
Controversies in Cardiac Surgery 3 years after SYNTAX : Percutaneous Coronary Intervention for Multivessel / Left main stem Coronary artery disease Pro ESC Congress 2010, 28 August 1 September Stockholm
More informationFFR-CT Not Ready for Primetime
FFR-CT Not Ready for Primetime Leslee J. Shaw, PhD, MASNC, FACC, FAHA, FSCCT R. Bruce Logue Professor of Medicine Co-Director, Emory Clinical CV Research Institute Emory University School of Medicine Atlanta,
More informationFFR? FFR-CT? Ischaemia testing?
FFR? FFR-CT? Ischaemia testing? Marco Zimarino, MD, PhD Institute of Cardiology - University G. d Annunzio, Chieti (Italy) Diagnostic management of patients with suspected stable CAD Risk stratification
More informationA Novel Simple Technique Using Hyperemia to Enhance Pressure Gradient Measurement of the Lower Extremity During Peripheral Intervention
A Novel Simple Technique Using Hyperemia to Enhance Pressure Gradient Measurement of the Lower Extremity During Peripheral Intervention Issam Koleilat, MD; Bruce Gray, MD From Greenville Health System,
More informationNovel insights into the complexity of ischaemic heart disease derived from combined coronary pressure and flow velocity measurements van de Hoef, T.P.
UvA-DARE (Digital Academic Repository) Novel insights into the complexity of ischaemic heart disease derived from combined coronary pressure and flow velocity measurements van de Hoef, T.P. Link to publication
More informationFractional Flow Reserve (FFR) --Practical Set Up Pressure Measurement --
Fractional Flow Reserve (FFR) --Practical Set Up Pressure Measurement -- JoonHyung Doh, MD, PhD Assistant Professor, Vision21 Cardiac and Vascular Center Inje University Ilsan Paik Hospital Goyang, Korea
More informationFFR in unstable angina and after MI F
FFR in unstable angina and after MI F June-Hong Kim, MD. PhD Cardiovascular center Pusan National University Yangsan Hospital FFR tells you physiologic stenosis severity rather than anatomical stenosis
More informationExpert Opinion on Fractional Flow Reserve-Guided Full Revascularisation of ST Segment Elevation Myocardial Infarction Patients
Expert Opinion on Fractional Flow Reserve-Guided Full Revascularisation of ST Segment Elevation Myocardial Infarction Patients Findings from the DANAMI-3 PRIMULTI Trial An interview with Thomas Engstrøm,
More informationIntervention: How and to which extent is technology helping us?
Cardiological Society of India Congress 12th February 2016 Chennai, India Intervention: How and to which extent is technology helping us? SIMONE BISCAGLIA MD CARDIOVASCULAR INSTITUTE, FERRARA, ITALY Introduction
More informationPercutaneous coronary intervention in patients with multi-vessel coronary artery disease: a focus on physiology
REVIEW Korean J Intern Med 2018;33:851-859 Percutaneous coronary intervention in patients with multi-vessel coronary artery disease: a focus on physiology Yun-Kyeong Cho and Chang-Wook Nam Division of
More informationFFR in Left Main Disease
FFR in Left Main Disease William F. Fearon, MD Associate Professor of Medicine Director, Interventional Cardiology Stanford University Medical Center Why FFR instead of IVUS? Physiologic versus anatomic
More informationFocus on Acute Coronary Syndromes
Focus on Acute Coronary Syndromes Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium Potential conflicts of interest Consulting fees and honoraria on my behalf go to the Cardiovascular
More informationDiagnostic Accuracy of Fractional Flow Reserve from Anatomic Computed TOmographic Angiography: The DeFACTO Study
Diagnostic Accuracy of Fractional Flow Reserve from Anatomic Computed TOmographic Angiography: The DeFACTO Study James K. Min 1 ; Jonathon Leipsic 2 ; Michael J. Pencina 3 ; Daniel S. Berman 1 ; Bon-Kwon
More informationFFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators
FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators Heart Vascular Stroke Institute, Samsung Medical Center, Seoul, Republic of
More informationPressureWire Aeris with Agile Tip Technology. Wireless FFR Functionality and Handles like a Workhorse PCI Guidewire 1
Home» Products» All International Products» PressureWire Aeris with Agile Tip Technology PressureWire Aeris with Agile Tip Technology This device is commercially available for use in select international
More informationFractional Flow Reserve Versus Angiography for Guiding Percutaneous Coronary Intervention in Patients With Multivessel Coronary Artery Disease
Journal of the American College of Cardiology Vol. 56, No. 3, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.04.012
More informationpat hways Medtech innovation briefing Published: 4 February 2014 nice.org.uk/guidance/mib2
pat hways The PressureWire fractional flow reserve measurement system for coronary artery disease Medtech innovation briefing Published: 4 February 2014 nice.org.uk/guidance/mib2 Summary Effectivenesseness
More informationControversies in Coronary Revascularization. Atlanta CCU April 15, 2016
Controversies in Coronary Revascularization Atlanta CCU April 15, 2016 Habib Samady MD FACC FSCAI Professor of Medicine Director, Interventional Cardiology, Emory University Director, Cardiac Catheterization
More informationDebate Should we use FFR? I will say NO.
Debate Should we use FFR? I will say NO. Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol Gwon Research fund from Abbott Korea
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationFractional Flow Reserve (FFR) estimation GRAIDIS CHRISTOS. EUROMEDICA-KYΑNOUS STAVROS Interventional Cardiologist, FSCAI
Fractional Flow Reserve (FFR) estimation Why, how, when? GRAIDIS CHRISTOS EUROMEDICA-KYΑNOUS STAVROS Interventional Cardiologist, FSCAI "Innovations in Interventional Cardiology & Electrophysiology IICE
More informationThe Latest on CT Fractional Flow Reserve. Dimitris Mitsouras, Ph.D.
The Latest on CT Fractional Flow Reserve Dimitris Mitsouras, Ph.D. Assistant Professor of Radiology Harvard Medical School Director, Applied Imaging Science Lab Brigham and Women s Hospital Disclosures
More informationCurrent and Future Imaging Trends in Risk Stratification for CAD
Current and Future Imaging Trends in Risk Stratification for CAD Brian P. Griffin, MD FACC Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic Disclosures: None Introduction
More informationPrimary Percutaneous Coronary Intervention
The big 5 in PCI Primary Percutaneous Coronary Intervention W. Wijns (Aalst, BE) Disclosures Consulting Fees: on my behalf go to the Cardiovascular Research Center Aalst Contracted Research between the
More informationSTEMI AND MULTIVESSEL CORONARY DISEASE
STEMI AND MULTIVESSEL CORONARY DISEASE ΤΣΙΑΦΟΥΤΗΣ Ν. ΙΩΑΝΝΗΣ ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΝΟΣ ΕΡΥΘΡΟΥ ΣΤΑΥΡΟΥ IRA 30-50% of STEMI patients have additional stenoses other than the infarct related
More informationJournal of the American College of Cardiology Vol. 61, No. 13, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 61, No. 13, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.065
More informationImaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD
Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD Hein J. Verberne Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands International Conference
More informationThe Impact of Sex Differences on Fractional Flow Reserve Guided Percutaneous Coronary Intervention
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 10, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2012.06.016
More informationThe importance of integrating coronary physiology into
Controversies in Cardiovascular Medicine Fractional Flow Reserve-Guided Percutaneous Coronary Intervention: Is it a Valid Concept? Percutaneous Coronary Intervention Should Be Guided by Fractional Flow
More informationIVUS vs FFR Debate: IVUS-Guided PCI
IVUS vs FFR Debate: IVUS-Guided PCI Gary S. Mintz, MD Cardiovascular Research Foundation New York, NY Disclosure Statement of Financial Interest Within the past 12 months, I have had a financial interest/arrangement
More informationHybrid cardiac imaging Advantages, limitations, clinical scenarios and perspectives for the future
Hybrid cardiac imaging Advantages, limitations, clinical scenarios and perspectives for the future Prof. Juhani Knuuti, MD, FESC Turku, Finland Disclosure: Juhani Knuuti, M.D. Juhani Knuuti, M.D. has financial
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More information21st Annual Contemporary Therapeutic Issues in Cardiovascular Disease
21st Annual Contemporary Therapeutic Issues in Cardiovascular Disease Noninvasive Evaluation of Coronary Artery Disease: Anatomical, Functional, Clinical May 5, 2018 Mark Hansen MD FRCPC Cardiologist,
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationCan We Safely Defer PCI. Yes, already proven
Can We Safely Defer PCI Just Based on FFR>0.80? Yes, already proven Seung-Jung Park, MD., PhD. Professor of Medicine, University of Ulsan, College of Medicine Heart Institute, Asan Medical Center, Seoul,
More informationCT-based myocardial ischemia evaluation: quantitative angiography, myocardial perfusion, and CT-FFR
CT-based myocardial ischemia evaluation: quantitative angiography, myocardial perfusion, and CT-FFR Poster No.: C-2641 Congress: ECR 2015 Type: Educational Exhibit Authors: H. J. Koo, D. H. Yang, J.-W.
More informationFFR and ifr: Similarities, Differences, and Clinical Implication
Annals of Nuclear Cardiology Vol. 3No. 1 53-60 REVIEW ARTICLE : Similarities, Differences, and Clinical Implication Hitoshi Matsuo, MD, PhD, Yoshiaki Kawase, MD and Itta Kawamura, MD, PhD Received: July
More informationWhat do the guidelines say?
Percutaneous coronary intervention in 3-vessel disease and main stem What do the guidelines say? Nothing to disclose Dariusz Dudek Institute of Cardiology, Jagiellonian University Krakow, Poland The European
More informationAngor Stable: de COURAGE à FAME 2. Maladie coronaire stable et coronarographie en De COURAGE à FAME 2
Maladie coronaire stable et coronarographie en 2013 De COURAGE à FAME 2 Bernard De Bruyne, MD, PhD Cardiovascular Center Aalst OLV-Clinic Aalst, Belgium COURAGE Trial Aim To compare optimal medical therapy
More informationHow to approach non-infarct related artery disease in patients with STEMI in a limited resource setting
How to approach non-infarct related artery disease in patients with STEMI in a limited resource setting Ahmed A A Suliman, MBBS, FACP, FESC Associate Professor, University of Khartoum Interventional Cardiologist,
More informationORIGINAL ARTICLE. Abstract. Introduction
ORIGINAL ARTICLE A Comparison between the Instantaneous Wave-free Ratio and Resting Distal Coronary Artery Pressure/Aortic Pressure and the Fractional Flow Reserve: The Diagnostic Accuracy CanBeImprovedbytheUseofbothIndices
More informationPrognostic Value of Gated Myocardial Perfusion SPECT
Current Use of IVUS & FFR George D. Dangas, MD, PhD, FACC, FSCAI Professor of Medicine Mount Sinai School of Medicine Prognostic Value of Gated Myocardial Perfusion SPECT 0.6% / year, Cardiac Death and
More informationFractional Flow Reserve (FFR) --Practical Set Up Pressure Measurement --
Fractional Flow Reserve (FFR) --Practical Set Up Pressure Measurement -- Joon Hyung Doh, MD, PhD Associate Professor, Division of Cardiology Inje University Ilsan Paik Hospital Goyang, Korea 목차 Fractional
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Coronary Computed Tomography Angiography with Page 1 of 23 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Coronary Computed Tomography Angiography with Professional
More informationCoronary Physiology and FFR. David H. Sibley MD FACC, FSCAI, FACP
Coronary Physiology and FFR David H. Sibley MD FACC, FSCAI, FACP Braunwald s Heart Disease, 7 th Edition Control of Coronary Blood Flow 1. CFR = max flow/basal flow and decreases with increasing stenosis
More informationChange in angiogram-derived management strategy of patients with chest pain when some FFR data are available: How consistent is the effect?
Accepted Manuscript Change in angiogram-derived management strategy of patients with chest pain when some FFR data are available: How consistent is the effect? Vinayak Nagaraja, Mamas Mamas, Michael Mahmoudi,
More informationName of Policy: Noninvasive Fractional Flow Reserve by Coronary Computed Tomographic Angiography
Name of Policy: Noninvasive Fractional Flow Reserve by Coronary Computed Tomographic Angiography Policy #: 635 Latest Review Date: August 2017 Category: Radiology Policy Grade: C Background/Definitions:
More information